Spectrum Pharmaceuticals - Chancen und Risiken? (Seite 144)

[HuntingParty]

Antwort auf Beitrag Nr.: 39.287.253 von VaJo am 07.04.10 14:24:37

Schön, dass Du Dich einen halben Tag, nachdem Du ein Urteil über ein Unternehmen gefällt hast, langsam anfängst, Dich mit dem Unternehmen zu beschäftigen. Zeugt von hoher Glaubwürdigkeit Deiner Aussagen.

Und es wäre schön, wenn Du dem Leser weiterhin erklärst wie die Aussage

Vajo: "Spectrum hat 50 Mio Aktien ausgegeben, keine Schulden und 125 Mio US-Dollar in Cash."

zum Balance Sheet (31.12.2009) passt. Dort liest man

Total Liabilities: 64,809 Mio. US-Dollar
Und der Cash ist auch niedriger als von Dir angegeben.

http://investor.spectrumpharm.com/releasedetail.cfm?ReleaseI…

Beenden wir besser die Diskussion. Erstens ist das ein Spectrum Thread. Zweitens hast Du Dich nicht wirklich mit Nuvo Research beschäftigt.

[VaJo]

Antwort auf Beitrag Nr.: 39.287.296 von VaJo am 07.04.10 14:29:37

Sorry mein Fehler nicht 333 Mio sondern 388 Mio fast 8x soviel

[VaJo]

Antwort auf Beitrag Nr.: 39.285.470 von HuntingParty am 07.04.10 10:44:51

Toller Vergleich - Spectrum hat 48 Mio Aktien Ausgegeben und Nuvo Research 333 Mio 6x soviel

[VaJo]

Antwort auf Beitrag Nr.: 39.285.470 von HuntingParty am 07.04.10 10:44:51

Pennsaid? Du weist aber schon das es bereits Diclofenac Pflaster von allen Generika Herstellern gibt. Auch in den USA. Ich glaube nicht das eine Diclofenac Salbe der Umsatz Bringer sein wird.
Hier wird mit versucht mit einem Generika Wirkstoff in anderer Verpackung Geld zu machen. Soll aber jeder glauben was er will. Nur mit Spectrum hat das herzlich wenig zu tun.

[HuntingParty]

Antwort auf Beitrag Nr.: 39.285.196 von VaJo am 07.04.10 10:16:31

Nein ich stelle nichts gleich:
Nuvo Research wird wegen der Pennsaid-Zulassung in den USA 2010 voraussichtlich einen positiven operativen Cashflow ausweisen (unabhängig von Einmalzahlungen).

Das Unternehmen ist daher entgegen Deiner Behauptung weder verschuldet noch hat es irgendwelche Cashprobleme. Und wenn Du, wie oben bei Nuvo Research, die laufenden Verbindlichkeiten dem Cashbestand gegenüberstellst bzw. die in der Vergangenheit erfolgte Verwässerung kritisierst, dann solltest Du das gleiche auch bei Spectrum machen. Denn auch da gab es die Ausgabe neuer Aktien und auch da gibt es laufende Verbindlichkeiten.

Daher bitte ich Dich einfach in Zukunft solche Schellschüsse zu unterlassen, wenn Du Dich nicht die aktuellen Zahlen und geschäftlichen Entwicklungen des beurteilten Unternehmens kennst.

[VaJo]

Antwort auf Beitrag Nr.: 39.285.069 von HuntingParty am 07.04.10 10:02:28

Kann es sein das du positiven Cashflow mit Einmaleffekten gleichstellst? Von daher ist SPPI seit 2 Jahren Cashflow Positiv.
Das wars jetzt von mir aber zu dem Thema.

[HuntingParty]

Antwort auf Beitrag Nr.: 39.284.930 von VaJo am 07.04.10 09:48:11

Hier die aktuellen Zahlen: Mit der Pennsaid-Zulassung in den USA und dem Covidien-Deal ist Nuvo für 2010 auch operativ profitabel.
Wenn Du mit veralteten Zahlen arbeitest wundert es mich auch nicht, dass Du bei Bioniche und Gentium Cashprobleme siehst.

Denn beide Unternehmen hatten Cashprobleme, die aber in den letzten Monaten gelöst wurden.



http://www.stockhouse.com/Bullboards/MessageDetail.aspx?s=NR…

Nuvo Research announces 2009 fourth quarter and year-end financial results


MISSISSAUGA, ON, Feb. 19 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the year and the fourth quarter ended December 31, 2009.


2009 Key Corporate Developments:

- Attained U.S. Food and Drug Administration (FDA) approval to market
the Company's lead drug Pennsaid(R), a topical non-steroidal anti-
inflammatory drug (NSAID), in the U.S.;

- Entered into a license and development agreement with Mallinckrodt
Inc., a subsidiary of Covidien plc (NYSE:COV), a leading global
provider of healthcare products, granting it exclusive rights to
market and sell Pennsaid, and its follow-on product, Pennsaid
Plus(R), in the United States;

- Awarded the bronze medal in the Science and Medical category of the
2009 Edison Awards for the Company's High Throughput Experimentation
Platform for the research and development of topical and transdermal
drug delivery formulations; and,

- Finished the year with $42.1 million in cash and cash equivalents,
which will be utilized to move Nuvo's internal pipeline of product
candidates forward, and potentially to acquire complementary late
stage products to fit within the Company's pipeline.


"In 2009, we laid the groundwork for Nuvo to mature into a profitable, diverse, drug development company with a focus on pain-related therapeutics," said Dan Chicoine, Chairman and Co-Chief Executive Officer of Nuvo Research. "We are eagerly anticipating Covidien's launch of Pennsaid in the first half of 2010. We believe that our best-in-class topical NSAID marketed by a partner like Covidien has the potential to generate significant revenue that will allow us to more aggressively invest in our pipeline and build our Company."


Financial Results:
(thousands of Canadian dollars)

-------------------------------------------------------------------------
THREE MONTHS ENDED YEAR ENDED
DECEMBER 31, DECEMBER 31,
----------------------- -----------------------
2009 2008 2009 2008
----------- ----------- ----------- -----------

Revenue $ 29,660 $ 3,117 $ 38,647 $ 10,727

Net income (loss) $ 22,275 $ (2,413) $ 15,018 $ (10,552)
-------------------------------------------------------------------------


Pennsaid FDA Approval

On November 4, 2009, the FDA approved the New Drug Application for Pennsaid permitting it to be sold and marketed in the United States. This approval significantly impacted the Company's fourth quarter results. The quarterly revenue includes $27.3 million in licensing fee revenue comprised of milestone and licensing payments received pursuant to the U.S. Licensing Agreement with Covidien. In addition, the Company incurred several costs directly related to the approval including:
.1 million, representing a 0.5% royalty payable to Paladin under the terms of its current licensing arrangements ("Royalty Payment") and a
.5 million milestone payment ("Milestone Payment") related to proprietary research. The net impact of these approval related items is an increase to net income of $26.7 million.

Operating Results

Revenue consisting of product sales, license fee revenue and research and other contract revenue for the three months ended December 31, 2009 was $29.7 million compared to $3.1 million for the three months ended December 31, 2008, an increase of $26.6 million. The increase was primarily attributable to licensing fee revenue of $27.3 million related to the U.S. Licensing Agreement (see Pennsaid FDA Approval), offset by a
.6 million reduction in product sales. This decrease in product sales was primarily attributable to lower sales of Pennsaid to Greece as the fourth quarter of 2008 was, and still represents, the highest quarterly sales to Nuvo's Greek distributor, Vianex. For the year, revenue increased significantly to $38.6 million from $10.7 million. The increase was primarily attributable to the licensing fee revenue earned pursuant to the U.S. Licensing Agreement with Covidien and an increase in Pennsaid product sales.


For the three months ended December 31, 2009, gross margin on product sales decreased to
.4 million compared to $1.0 million for the three months ended December 31, 2008. The decrease in gross margin was primarily attributable to a decrease in Pennsaid sales and sales of WF10 based products and the impact of higher raw material prices versus a year ago. For the year, gross margin on product sales was $3.3 million compared to $3.2 million for the year ending December 31, 2008. The increase in gross margin was primarily attributable to higher Pennsaid sales, offset partially by higher material costs, the strengthening U.S. dollar and costs related to the capacity expansion at the Company's manufacturing facility in Varennes, Quebec.


Total operating expenses, excluding foreign currency losses, for the three months ended December 31, 2009 were $5.6 million versus $5.0 million for the three months ended December 31, 2008. The increase in the quarter relates primarily to higher research and development expenses and selling, general and administrative expenses. Total operating expenses, excluding foreign currency losses, for the year ended December 31, 2009 increased slightly to $17.4 million compared to $17.1 million for the year ended December 31, 2008. The increase from 2008 relates to higher selling, general and administrative expenses, offset by lower research and development expenses, stock-based compensation and amortization expense.


Research and development expenses were $3.0 million for the three months ended December 31, 2009, compared with $2.5 million for the three months ended December 31, 2008. The increase in the quarter relates to the Milestone Payment and severance, while other R&D spending was lower as the fourth quarter of 2008 included expenses related to completing studies for the Company's Complete Response to the Pennsaid Approvable Letter. For the year, research and development was $8.6 million compared to $9.3 million for the year ending December 31, 2008. The decrease for the year relates to reduced spending on Pennsaid and Pennsaid Plus, offset by increases in costs related to research and formulation development activities at the Company's research labs in San Diego and severance costs.


SG&A expenses increased to $2.2 million for the three months ended December 31, 2009, compared to $1.6 million for the three months ended December 31, 2008. The increase in the quarter relates primarily to the Royalty Payment, compensation expense and severance. For the year ended December 31, 2009, SG&A expenses increased to $7.0 million compared to $5.2 million for the year ended December 31, 2008. The increase was primarily attributable to increased compensation expense, legal fees and the Royalty Payment.


For the three months and year ended December 31, 2009, net income was $22.3 million and $15.0 million compared to net losses of $2.4 million and $10.6 million for the three months and year ended December 31, 2008, respectively. The significant increase in both periods relates to the Pennsaid FDA Approval related items.


Cash and cash equivalents on hand at December 31, 2009 of $42.1 million were $12.6 million more than the $29.5 million at September 30, 2009. The increase was almost entirely attributable to cash received for the FDA Approval Payment, offset partially by other net spending during the quarter.


Cash provided by operating activities of $12.9 million was significantly higher than the cash used in operating activities of $4.2 million for the three-month period ended December 31, 2008 due to receipt of the FDA Approval Payment and a recovery of the Company's investment in non-cash working capital due primarily to lower accounts receivable and an increase in accounts payable and bonus and severance accruals at December 31, 2009. For the year ended December 31, 2009, cash provided by operating activities was $16.3 million compared to cash used in operating activities of $9.1 million for the year ended December 31, 2008.


Notice of Annual and Special Meeting

Nuvo will be holding its Annual and Special Meeting on Thursday, April 29, 2010 at 9:00 a.m. (EST) at One King West (The Austin Gallery), 1 King Street West, Toronto, Ontario, Canada.


About Nuvo Research Inc.


Nuvo is primarily focused on the research and development of drug products delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immunomodulating drug candidate WF10. Nuvo's lead product is Pennsaid, a topical non-steroidal anti-inflammatory drug (NSAID), which is currently sold in Canada and several European countries. Pennsaid was approved for marketing in the U.S. by the FDA on November 4, 2009. The commercial launch of Pennsaid in the U.S. by Covidien is scheduled for the first half of 2010. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications. Nuvo is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany, and research and development centers in San Diego, California and Leipzig, Germany. For more information, please visit www.nuvoresearch.com.


Summary financial statements attached

[VaJo]

Antwort auf Beitrag Nr.: 39.284.930 von VaJo am 07.04.10 09:48:11

Spectrum hat 50 Mio Aktien ausgegeben, keine Schulden und 125 Mio US-Dollar in Cash. Ohne Pipelinebetrachtung sind das allein schon Hammerzahlen. Nimmt man die Pipeline hinzu müßte die Aktie bei +15 Dollar stehen.

[VaJo]

Antwort auf Beitrag Nr.: 39.284.820 von HuntingParty am 07.04.10 09:38:49

Nuvo Research
3. Quartal 2009

388 Mio Shares
Cash 29 Mio
Schulden 21 Mio
Umsatz 2,5 Mio
Verlust 2,7 Mio
Nettoverlust 3,88 Mio

Ich seh hier nur genauso viel Cash wie Schulden, bei einer irren Anzahl von Shares die darauf schließen lassen das Nuvo sich regelmäßig Geld durch Ausgabe neuer Aktien beschafft.

Das Ergebnis zum 4. Quartal kann ich nicht finden.

[HuntingParty]

Antwort auf Beitrag Nr.: 39.284.662 von VaJo am 07.04.10 09:21:54

Alle diese Unternehmen sind verschuldet und haben Cashproble…

Dann erklär doch mal dem geneigten Leser, wo die Cashprobleme oder die Verschuldung z.B. von Nuvo Research liegen.

Ansonsten kann ich Dich nach dieser pauschalen Schnellschußantwort nicht mehr ernst nehmen.